News
11/6/2015

CEXS-UPF: INPACT, an international Project for the preclinic development of innovative drugs

CEXS-UPF: INPACT, an international Project for the preclinic development of innovative drugs


News from CEXS-UPF


INPACT, "Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training, and communication", aims for the preclinical development of innovative drugs with specific formulations against determined types of cancer as prostate cancer, and determined pathogenic bacteria, like Staphylococcus aureus.

The project's Consortium consists of four academic partners (Australia, Brazil, Spain and Portugal) and three technology companies that provide their own technologies for achieving innovative drugs. David Andreu, group leader of the Proteomics and Protein Chemistry Unit from the Department of Experimental and Health Sciences (CEXS), takes part of the project as a peptide expert academic partner.

More information:
CEXS-UPF website